deferiprone has been researched along with ALS - Amyotrophic Lateral Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouchaoui, H; Cabantchik, ZI; Danel, V; Devedjian, JC; Devos, D; Duce, JA; Gouel, F; Mahoney-Sanchez, L; Moreau, C; Rolland, AS | 1 |
| Auger, F; Blasco, H; Bordet, R; Cabantchik, ZI; Corcia, P; Danel, V; Defebvre, L; Devedjian, JC; Devos, D; Duce, J; Duhamel, A; Dupuis, L; Dutheil, M; Garçon, G; Gouel, F; Grolez, G; Jonneaux, A; Kuchcinski, G; Kyheng, M; Lachaud, C; Laloux, C; Lopes, R; Moreau, C; Oeckl, P; Otto, M; Pérez, T; Petrault, M; Pradat, PF; Timmerman, K; Veyrat-Durebex, C | 1 |
1 review(s) available for deferiprone and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating Agents; Parkinson Disease | 2020 |
1 trial(s) available for deferiprone and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Deferiprone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Male; Mice; Mice, Transgenic; Middle Aged; Neuroprotective Agents; Oxidative Stress; Young Adult | 2018 |